1. Trang chủ
  2. » Y Tế - Sức Khỏe

Adrenocortical Carcinoma Basic Science and Clinical Concepts ppt

562 695 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Cấu trúc

  • Adrenocortical Carcinoma: Basic Science and Clinical Concepts

  • Front-matter

    • Title page

    • Copyright

    • Preface

    • Contents

    • Contributors

  • Part I History of Adrenocortical Carcinoma Research and Clinical Care

    • 1 The History of Adrenocortical Carcinoma Treatment A Medical Perspective

      • References

    • 2 The History of Adrenocortical Carcinoma Treatment A Surgical Perspective

      • References

  • Part II Epidemiology, Presentation and Diagnosis

    • 3 Epidemiology of Adrenocortical Carcinoma

      • 3.1 Incidence of Adrenocortical Carcinoma

      • 3.2 Risk Factors for Adrenocortical Carcinoma

      • 3.3 Stage at Presentation

      • 3.4 Prognosis of Adrenocortical Carcinoma

      • 3.5 Associated Malignancies

      • References

    • 4 Clinical Presentation and Initial Diagnosis

      • 4.1 Clinical Presentation

        • 4.1.1 Hormone Excess

        • 4.1.2 Loco-Regional Manifestations

        • 4.1.3 Unspecific Symptoms -- Metastatic Disease

        • 4.1.4 Incidentally Detected Adrenocortical Carcinoma

      • 4.2 Laboratory Work-Up

      • 4.3 Imaging at Presentation

      • 4.4 Fine-Needle Aspiration/Cut Biopsy

      • References

    • 5 Diagnostic Approach to Incidentaloma

      • 5.1 Does the Adrenal Lesion Exhibit a Biologically Benign or Malignant Behavior?

        • 5.1.1 Evidence from Epidemiological Studies -- Adrenocortical Tumors

        • 5.1.2 Evidence from Epidemiological Studies -- Pheochromocytomas

        • 5.1.3 Evidence from Epidemiological Studies -- Metastasis

        • 5.1.4 Evidence from Epidemiological Studies -- Other Adrenal Lesions

        • 5.1.5 Evidence from Imaging Studies

        • 5.1.6 Evidence from Biopsy Studies

      • 5.2 Is the Adrenal Lesion a Source of Autonomous Hormone Hypersecretion?

        • 5.2.1 Evidence from Epidemiological Studies

        • 5.2.2 Hormone Excess

          • 5.2.2.1 Hypercortisolism

          • 5.2.2.2 Hyperaldosteronism

          • 5.2.2.3 Pheochromocytoma

          • 5.2.2.4 Hyperandrogenemia

          • 5.2.2.5 Other Endocrine Functions

      • 5.3 Is Surgical Removal Necessary or Is an Observational Policy a Safe and Reasonable Approach?

      • References

  • Part III Imaging

    • 6 Computed Tomography/Magnetic Resonance Imaging of Adrenocortical Carcinoma

      • 6.1 Clinical Utility of CT and MRI

      • 6.2 Pheochromocytoma

      • 6.3 The Incidentally Discovered Adrenal Mass (Incidentaloma)

      • 6.4 Myelolipoma

      • 6.5 Cyst

      • 6.6 Hemorrhage

      • 6.7 Adrenocortical Adenoma

      • 6.8 Adrenocortical Carcinoma

      • 6.9 Metastasis

      • 6.10 Differential Diagnosis: Adrenocortical Adenoma or Metastasis?

      • 6.11 Differential Diagnosis: Adrenocortical Adenoma or Carcinoma?

      • 6.12 Imaging and Staging of Adrenocortical Carcinoma

      • References

    • 7 Functional Imaging of Adrenocortical Carcinoma

      • 7.1 [18F]-FDG-PET-CT in Adrenocortical Carcinoma

      • 7.2 Molecular Imaging with Specific Adrenocortical Tracers

        • 7.2.1 Norcholesterol Scintigraphy

        • 7.2.2 Enzyme Inhibitors

        • 7.2.3 Metomidate

        • 7.2.4 [18F]-Fluoro-etomidate

        • 7.2.5 [123I /131I]-Iodo-metomidate

      • References

  • Part IV Pathology

    • 8 Classical Histopathology and Immunohistochemistry

      • 8.1 Gross Findings

      • 8.2 Histopathology

      • 8.3 Scoring Systems

      • 8.4 Immunocytochemistry

      • 8.5 Ultrastructure

      • 8.6 Grading

      • 8.7 Staging

      • 8.8 Differential Diagnosis

      • References

    • 9 Cellular and Molecular Pathology of Adrenocortical Carcinoma

      • 9.1 Clonality

      • 9.2 Genomic and Genetic Abnormalities

        • 9.2.1 Ploidy and DNA Content of Adrenocortical Tumors

        • 9.2.2 Genomic Aberrations in Adrenocortical Carcinoma: Analysis by Comparative Genomic Hybridization (CGH)

        • 9.2.3 LOH and Mutation Analysis of Genomic Loci and Genes

      • 9.3 The RAS-Associated Signaling Networks in Adrenocortical Carcinoma

      • 9.4 Angiogenesis in Adrenocortical Carcinoma

      • 9.5 Peptide Hormones and Cytokines in Adrenocortical Carcinoma

      • 9.6 Contributions of Physiological Regulators of the HPA-Axis, ACTH, and Steroid Hormones to Adrenocortical Tumorigenesis

      • 9.7 Timing of the Occurrence of Tumorigenesis-Related Changes

      • References

  • Part V Genetic and Molecular Aspects

    • 10 Overview of Genetic Syndromes Associated with Adrenocortical Cancer

      • 10.1 Syndromes Associated with Adrenocortical Cancer

        • 10.1.1 The Overgrowth Syndromes: BWS and IHH

        • 10.1.2 Li--Fraumeni Syndrome

        • 10.1.3 Familial Adenomatous Polyposis

        • 10.1.4 Multiple Endocrine Neoplasia Type 1

        • 10.1.5 Neurofibromatosis Type 1

      • 10.2 Screening for Germline Mutations in Adrenocortical Cancer Patients

      • 10.3 Screening and Surveillance of Patients with Hereditary Syndromes Predisposing to Adrenocortical Cancer

      • References

    • 11 LiFraumeni Syndrome

      • 11.1 Clinical Definition of LFS

      • 11.2 Cancer Risk Patterns in LFS Families

      • 11.3 The TP53 Tumor Suppressor

      • 11.4 TP53 Gene Inactivation

      • 11.5 TP53 and the LFS

      • 11.6 The Role of Other Genes in LFS

      • 11.7 Modifier Genes in LFS

      • 11.8 The Unique Brazilian LFS-TP53Codon 337 Mutation Phenotype

      • 11.9 Functional Models of Germline TP53 Mutations

      • 11.10 Mouse Models of LFS

      • 11.11 Medical and Ethical Considerations

      • References

    • 12 TP53 Molecular Genetics

      • 12.1 The Pre-eminent Tumor Suppressor

      • 12.2 Transcription Is Key

      • 12.3 The TP53 Signaling Pathway: Loops Within Loops

      • 12.4 Acquired and Inherited TP53 Mutations

      • 12.5 TP53 Mutations in Childhood and Adult Adrenocortical Tumors

      • 12.6 Low-Penetrance Mutant TP53 Alleles

      • 12.7 Genetic Modifiers

      • 12.8 Concluding Thoughts

      • References

    • 13 Telomeres and Telomerase in Adrenocortical Carcinoma

      • 13.1 The End-Replication Problem and Telomerase

      • 13.2 Telomeres

      • 13.3 Telomere-Based Model of Carcinogenesis

      • 13.4 Telomerase in Experimental Adrenocortical Carcinoma

      • 13.5 Human Syndromes with Defects in Telomere Physiology

      • 13.6 Telomerase and Adrenocortical Carcinoma

      • 13.7 Telomeres and Adrenocortical Carcinoma

      • References

    • 14 Beckwith--Wiedemann Syndrome

      • 14.1 Diagnosis

      • 14.2 Clinical Features

      • 14.3 Genetics

      • 14.4 Cancer

      • References

    • 15 The Insulin-Like Growth Factor System in Adrenocortical Growth Control and Carcinogenesis

      • 15.1 The IGF System

      • 15.2 The Role of the IGF System in the Normal Adult Adrenal Gland

        • 15.2.1 Insulin-Like Growth Factors

        • 15.2.2 IGF Receptors

        • 15.2.3 IGF-Binding Proteins

      • 15.3 Specific Role of the IGF System in Adrenocortical Tumorigenesis

        • 15.3.1 IGF1

        • 15.3.2 IGF2

      • 15.4 IGF Receptors

        • 15.4.1 The IGF1R

        • 15.4.2 The IGF2/Mannose-6-Phosphate (IGF2R)-Receptor

      • 15.5 IGFBPs

      • 15.6 Summary and Conclusion

      • References

    • 16 WNT/-Catenin Signaling in Adrenocortical Carcinoma

      • 16.1 The WNT/-Catenin Signaling Pathway

        • 16.1.1 Molecular Mechanisms of the Canonical WNT/-Catenin Signaling Pathway

        • 16.1.2 Components of the WNT/-Catenin Signaling Pathway

          • 16.1.2.1 Initiation of the WNT/-Catenin Signaling Pathway at the Cell Membrane

          • 16.1.2.2 WNT/-Catenin Signaling Events in the Cytoplasm

          • 16.1.2.3 Nuclear Components of the WNT/-Catenin Signaling Pathway

        • 16.1.3 The WNT/-Catenin Signaling Pathway Target Genes

      • 16.2 The WNT/-Catenin Signaling Pathway in Familial Adenomatous Polyposis Coli

      • 16.3 The WNT/-Catenin Signaling Pathway in the Adrenal Cortex and in Adrenocortical Tumors

        • 16.3.1 Adrenal Cortex Development

        • 16.3.2 Adrenocortical Diseases

      • 16.4 The WNT Signaling Pathway in Adrenocortical Carcinoma

        • 16.4.1 Activation of the WNT/ -Catenin Pathway and -Catenin Mutations

        • 16.4.2 Role of -Catenin Activation in Adrenocortical Tumor Development

        • 16.4.3 Alternatives to CTNNB1 Mutation for WNT/-Catenin Pathway Activation in Adrenocortical Carcinoma

          • 16.4.3.1 WTX, AXIN1, AXIN2, or GSK3

          • 16.4.3.2 APC

      • 16.5 The WNT/-Catenin Signaling Pathway: A Potential Target for Cancer Treatment

      • 16.6 Conclusion

      • References

  • Part VI Models of Adrenocortical Cancer

    • 17 Adrenocortical Stem and Progenitor Cells: Implications for Cancer

      • 17.1 Adrenocortical Tumors

      • 17.2 Normal Adrenal Adult Stem Cells

        • 17.2.1 Adrenal Development and Structure

        • 17.2.2 Where Do the Adrenal Adult Stem Cells Reside?

        • 17.2.3 Establishment of the Stem Cell Niche

          • 17.2.3.1 Adrenal Precursor Cells in Fetal Zone

          • 17.2.3.2 Stem/Progenitor Cells in Adrenal Capsule

      • 17.3 What Factors Regulate Adrenal Adult Stem and Progenitor Cells?

        • 17.3.1 Dax1

        • 17.3.2 Shh

        • 17.3.3 Wnt/-Catenin

        • 17.3.4 IGF2

        • 17.3.5 Telomerase

      • 17.4 How Do Normal Adrenal Cells Become Cancer Cells/or How Is Adrenocortical Carcinoma Initiated?

        • 17.4.1 Wnt/-Catenin

        • 17.4.2 IGF2

        • 17.4.3 Pod1

        • 17.4.4 p53/Telomerase

      • 17.5 How Is Adrenocortical Carcinoma Maintained: Cancer Stem Cell or Stochastic Model?

      • 17.6 Summary

      • References

    • 18 Adrenocortical Cell Lines

      • 18.1 Human Adrenocortical Cell Lines

        • 18.1.1 The NCI-H295, NCI-H295R, and NCI-H295A Adrenocortical Carcinoma Cell Lines

          • 18.1.1.1 Origin and Development

          • 18.1.1.2 Cell Line Growth and Characterization

          • 18.1.1.3 Expression of Hormone Receptors and Hormonal Responsiveness

          • 18.1.1.4 Steroidogenesis

          • 18.1.1.5 Steroidogenic Enzyme Expression

          • 18.1.1.6 NCI-H295 Cell Line As Adrenal Cancer Therapy Tool

        • 18.1.2 Human Adrenocortical Carcinoma, Clone 15 (HAC15) Cell Line, and Related Clones

        • 18.1.3 Pediatric Adrenocortical Adenoma Derived Cell Line

          • 18.1.3.1 Origin and Development

          • 18.1.3.2 Growth and Steroidogenesis

        • 18.1.4 The SW13 Human Adrenal Carcinoma Derived Cell Line

        • 18.1.5 The ACT-1 Human Adrenal Carcinoma Derived Cell Line

        • 18.1.6 The RL-251 Human Adrenal Carcinoma Derived Cell Line

        • 18.1.7 Human Adrenal Cell Lines from Viral Oncogenes

      • 18.2 Rodent Adrenocortical Cell Lines

        • 18.2.1 The Y1 Adrenal Cell Line

        • 18.2.2 Experimentally Induced Rodent Adrenal Cell Lines

      • 18.3 Bovine Adrenocortical Cell Lines

      • 18.4 Summary

      • References

    • 19 Mouse Models of Adrenal Tumorigenesis

      • 19.1 Mouse Models with Spontaneous or Induced Adrenal Tumor Growth

      • 19.2 Mouse Models Utilizing Transplanted Adrenal Tumor Cells

      • 19.3 Genetically Modified Mouse Models with an Adrenal Tumor Phenotype

      • 19.4 Mouse Models with Transgenic Expression of an Oncogene-Inducing Adrenal Tumor

      • 19.5 Mouse Models with Targeted Deletions Inducing Adrenal Tumors

      • References

  • Part VII Therapies

    • 20 Overview of Treatment Options for Adrenocortical Carcinoma

      • 20.1 Adjuvant Treatment

      • 20.2 Treatment of Metastatic Disease

      • 20.3 Medical Treatment of Adrenocortical Carcinoma Steroidogenic Hormone Excess

      • 20.4 Emerging Therapies

      • References

    • 21 Chemotherapy

      • 21.1 Single-Agent Chemotherapy

      • 21.2 Combination Chemotherapy

      • 21.3 Chemotherapy Plus Mitotane

      • 21.4 Chemotherapy Plus Target Therapy

      • 21.5 The FIRM-ACT Study

      • 21.6 Prognostic and Predictive Factors of Response to Chemotherapy in Advanced Patients

      • 21.7 Conclusion

      • References

    • 22 Mitotane

      • 22.1 Pharmacokinetics

      • 22.2 Historical Background

      • 22.3 Mitotane in Advanced Adrenocortical Carcinoma

      • 22.4 Toxicity and Dosage

      • 22.5 Mitotane in Adjuvant Setting

      • References

    • 23 Pharmacotherapy for Hormone Excess in AdrenocorticalCarcinoma

      • 23.1 Adrenal Steroid Biosynthesis

        • 23.1.1 Basics of Adrenal Steroidogenesis and Zonation

        • 23.1.2 Steroidogenic Enzymes

        • 23.1.3 Steroidogenic Pathways in the Adrenal Gland

        • 23.1.4 Acute and Chronic Regulation of Adrenal Steroidogenesis and Dysregulation in Adrenocortical Carcinoma

      • 23.2 Approach to the Adrenocortical Carcinoma Patient

        • 23.2.1 Clinical Manifestations of Adrenal Steroid Excess

        • 23.2.2 Therapeutic Strategies

      • 23.3 Specific Treatments

        • 23.3.1 Mineralocorticoid Excess

          • 23.3.1.1 Inhibitors of Mineralocorticoid Synthesis

          • 23.3.1.2 Mineralocorticoid Receptor Antagonists

          • 23.3.1.3 Nonspecific Treatment of Hypertension and Hypokalemia

        • 23.3.2 Glucocorticoid Excess

          • 23.3.2.1 Inhibitors of Glucocorticoid Synthesis

          • 23.3.2.2 Glucocorticoid Receptor Antagonists

          • 23.3.2.3 Nonspecific Treatment of Cardiovascular and Metabolic Consequences

        • 23.3.3 Androgen Excess

          • 23.3.3.1 Inhibitors of Androgen Synthesis

          • 23.3.3.2 Androgen Receptor Antagonists

          • 23.3.3.3 Nonspecific Treatment of Androgen Excess

        • 23.3.4 Treatment of Estrogen Excess

      • 23.4 Conclusions

      • References

    • 24 Surgery for Adrenocortical Carcinoma

      • 24.1 Surgical Adrenal Anatomy

        • 24.1.1 Arterial Supply

        • 24.1.2 Venous Drainage

        • 24.1.3 Lymphatics

        • 24.1.4 Adjacent Structures

      • 24.2 Perioperative Considerations

        • 24.2.1 Preoperative

        • 24.2.2 Intraoperative

        • 24.2.3 Postoperative

      • 24.3 Role of Surgery

        • 24.3.1 Primary Therapy -- Curative Intent

        • 24.3.2 Recurrences

        • 24.3.3 Palliation: Hormonal Control and Tumor Debulking

      • 24.4 Surgical Approaches to the Adrenal Glands

        • 24.4.1 Anterior Transabdominal -- Open

        • 24.4.2 Thoracoabdominal

        • 24.4.3 Approaches to Difficult Resections

          • 24.4.3.1 Vascular Control and Resection

        • 24.4.4 Laparoscopic Surgery for Primary Adrenal Malignancy

      • 24.5 Surgical Complications

      • 24.6 Conclusion

      • References

    • 25 Radiation Therapy for Adrenocortical Carcinoma

      • 25.1 Current Surgical and Adjuvant Management

      • 25.2 Radiotherapy for Adrenocortical Carcinoma

      • 25.3 Case Studies

        • 25.3.1 Case #1. Adjuvant Radiotherapy

        • 25.3.2 Case #2. Adjuvant Radiotherapy After Resection of a Local Recurrence

        • 25.3.3 Case #3. Palliation of a Bulky Liver Metastasis

      • 25.4 Summary

      • References

    • 26 Follow-Up and Monitoring of Adrenocortical Carcinoma

      • 26.1 General Modalities for Follow-Up

      • 26.2 History

      • 26.3 Physical Examination

      • 26.4 Laboratory Evaluation

      • 26.5 Imaging

        • 26.5.1 Symptom-Specific/Sign-Specific Imaging

        • 26.5.2 Cross-Sectional Imaging

        • 26.5.3 Functional Imaging

      • 26.6 Risk-Based Follow-Up Strategies

        • 26.6.1 Low-Risk Localized Disease/Complete Resection

        • 26.6.2 High-Risk Disease/Complete Resection

        • 26.6.3 Unresectable Localized or Metastatic Disease

      • 26.7 Risk Modifiers and Follow-Up Strategies

      • 26.8 Conclusion

      • References

  • Part VIII Unique Cohorts and Future Perspectives

    • 27 Aldosterone-Producing Adrenocortical Carcinoma

      • 27.1 Epidemiology

      • 27.2 Clinical and Hormonal Features

      • 27.3 Pathology

      • 27.4 Imaging Characteristics

      • 27.5 Prognosis

      • 27.6 Treatment

      • References

    • 28 Adrenocortical Cancer in Children

      • 28.1 Epidemiology of Adrenocortical Cancer

      • 28.2 Biology of Adrenocortical Carcinoma

      • 28.3 Clinical Characteristics of Pediatric Adrenocortical Carcinoma

      • 28.4 Diagnosis of Adrenocortical Carcinoma

      • 28.5 Prognostic Factors

      • 28.6 Treatment of Pediatric Adrencortical Carcinoma

      • 28.7 A Collaborative Research Initiative for Childhood Adrenocortical Carcinoma

      • References

    • 29 Genome-Wide Studies in Adrenocortical Neoplasia

      • 29.1 Introduction and the Potential of Genomic Studies

      • 29.2 Genome-Wide Gene Expression Studies

      • 29.3 Array-Based Comparative Genomic Hybridization

      • 29.4 MicroRNA Profiling

      • 29.5 Molecular Profiling and Its Potential Impact on Adrenal Pathology and Management of Patients with Adrenal Cancer

        • 29.5.1 Diagnosis

        • 29.5.2 Prognosis

        • 29.5.3 Prediction

      • 29.6 Conclusion

      • References

    • 30 New Strategies for the Treatment of Adrenocortical Carcinoma

      • 30.1 Therapy Targeted Towards Altered Signaling Pathways in Adrenocortical Carcinoma Cells

        • 30.1.1 Identification of Potential Signaling Targets

          • 30.1.1.1 Target Identification from the Study of Genetic Syndromes

          • 30.1.1.2 Targets Identified from Gene Expression Analysis

        • 30.1.2 Targeting the IGF2-IGF1R Pathway

          • 30.1.2.1 Small Molecule TKIs

          • 30.1.2.2 Anti-IGF1R Antibodies

        • 30.1.3 Targeting the FGF Receptor

        • 30.1.4 Targeting the EGF Receptor

        • 30.1.5 Multi-kinase Inhibition Strategies

        • 30.1.6 Targeting the Wnt Signaling Pathway

      • 30.2 Enhancing the Effectiveness of Cytotoxic Chemotherapy

      • 30.3 Proapoptoic Strategies

      • 30.4 Novel Strategies

        • 30.4.1 Targeting Tumor Vasculature

        • 30.4.2 Targeting the Microenvironment

          • 30.4.2.1 Fibroblasts of the Microenvironment

          • 30.4.2.2 Immune Cells of the Microenvironment

          • 30.4.2.3 Proteolytic Enzymes in the Microenvironment

        • 30.4.3 Therapy Aimed at Metastasis Suppression

      • 30.5 Delivery of Newer Modes of Therapy

      • 30.6 Summary and Future Directions

      • References

  • Part IX Adrenal Cancer Networks and Registries

    • 31 The Dutch Adrenal Network

      • 31.1 The Dutch Adrenal Network

      • 31.2 The Dutch Adrenal Registry

      • 31.3 Results

      • 31.4 Future Goals

      • 31.5 Conclusion

    • 32 The ENS@T Initiative

      • 32.1 The History: From National Networks to ENS@T

      • 32.2 Increasing the Patient Number

      • 32.3 Increasing Technical and Methodological Exchange

      • 32.4 The Idea of Exchange

        • 32.4.1 Harmonization

        • 32.4.2 Material

        • 32.4.3 Science

      • 32.5 Examples of Research Advancements

      • 32.6 Organizing the Network

        • 32.6.1 The Steering Committee

        • 32.6.2 The Working Groups

        • 32.6.3 ENS@T Website

      • 32.7 Financing the Network

      • 32.8 Perspectives

        • 32.8.1 Integrational and Disseminative Effects of a European Network

      • References

  • Index

Nội dung

[...]... gerard.zambetti@stjude.org Part I History of Adrenocortical Carcinoma Research and Clinical Care Chapter 1 The History of Adrenocortical Carcinoma Treatment – A Medical Perspective David E Schteingart Knowledge of the genetic and molecular alterations in adrenocortical carcinoma (ACC) has advanced in the past two decades, as a result of newer laboratory methodology to study mechanisms of oncogenesis and tumor pathophysiology... et al (1979) Cushing’s syndrome due to adrenocortical carcinoma Acta Endocrinologica 91:303–318 29 Lewinsky BS et al (1974) The clinical and pathologic features of “non-hormonal” adrenocortical tumors Cancer 33:778–790 30 Lipsett MB et al (1963) Clinical and pathophysiologic aspects of adrenocortical carcinoma Am J Med 35:374–383 31 Richie JP, Gittes RE (1980) Carcinoma of the adrenal cortex Cancer... (1983) Adrenocortical carcinoma In: Thompson NW, Vinik AI (eds) Endocrine surgery update Grune and Stratton, New York, pp 119–128 7 Luton JP et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy N Engl J Med 322:1195–1201 8 Hogan TF et al (1978) o,p -DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity and. .. Am Physicians 48:224–235 24 Thompson NW (1983) Adrenocortical carcinoma. In: Thompson NW, Vinik AI (eds) Endocrine surgery update Grune and Straton, New York 25 Sahteingart DE et al (1982) Treatment of adrenal carcinomas Arch Surg 117:1142–1147 26 Cohn K et al (1986) Adrenocortical carcinoma Surgery 100:1170–1177 27 Icard P et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective... T Broome Vanderbilt Endocrine Surgery Center, Vanderbilt University, 597 Preston Research Building, 2220 Pierce Ave, Nashville, TN, USA, james.broome@vanderbilt.edu Maria V Cicala Division of Endocrinology, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 105, 35128 Padova, Italy, mariaverena.cicala@unipd.it Fulvia Daffara Department of Clinical and Biological Sciences,... adrenal tumors, four of which were carcinomas One tumor was palpable, one was seen on x-ray, and three found at operation Three developed acute adrenocortical failure, and one of them who was treated in 1923 before cortical extract was available died The other two received cortical extracts and recovered Three of the five with tumors 2 The History of Adrenocortical Carcinoma Treatment – A Surgical Perspective... disease With cardiopulmonary bypass and cold arrest, tumor thrombus into right atrium excised and endovenectomy of all tumors in vena cava and both left and middle hepatic veins excised A pericardial patch was used for the vena cava and distal hepatic veins The patient had an uneventful course with complete relief of the Budd Chiari syndrome 2 The History of Adrenocortical Carcinoma Treatment – A Surgical... toxicity and steroid replacement Cancer 42:2177–2181 9 Bilimoria KY et al (2008) Adrenocortical carcinoma in the United States Treatment utilization and prognostic factors Cancer 113(11):3130–3136 Chapter 2 The History of Adrenocortical Carcinoma Treatment – A Surgical Perspective Norman W Thompson The early history of adrenocortical carcinoma (ACC) is obscure because of the rarity of the disease, confusing... manifestations, and a vague appreciation of its clinical course Most reported cases in the 19th century were based on autopsy findings, and the tumors were classified by a variety of terms including hypernephroma, sarcoma, fibromyxosarcoma, and carcinoma The commonly used term, hypernephroma, was first proposed by Grawitz et al in 1893 and falsely assumed that tumors arose in rests of adrenocortical tissue... (1987) Adrenocortical carcinoma CA Cancer J Clin 37:348–365 2 Soffer LJ et al (1961) The human adrenal gland Lea & Febiger, Philadelphia, PA 3 Cecil HF (1933) Hypertension, obesity, virilism and pseudohermaphroditism as caused by suprarenal tumors J.A.M.A 100:463 4 Eisenstein AB (1967) The adrenal cortex Little, Brown and Company, Boston, MA 5 Schteingart DE et al (1982) The treatment of adrenal carcinoma .

Ngày đăng: 29/03/2014, 08:20

TỪ KHÓA LIÊN QUAN